<abstract xml:lang="en" xmlns="http://www.w3.org/1999/xhtml">[61Cu]diacetyl-<italic>bis</italic>(N4-methylthiosemicarbazone) ([61Cu] ATSM) was prepared using in house-made diacetyl-<italic>bis</italic>(N4-methylthiosemicarbazone) (ATSM) ligand and [61Cu]CuCl2 produced <italic>via</italic> the natZn(p, x)61Cu (180 μA proton irradiation, 22 MeV, 3.2 h) and purified by a ion chromatography method. [61Cu]ATSM radiochemical purity was >98 %, as shown by HPLC and RTLC methods. [61Cu]ATSM was administered into normal and tumor bearing rodents for up to 210 minutes, followed by biodistribution and co-incidence imaging studies. Significant tumor/non-tumor accumulation was observed either by animal sacrification or imaging. [61Cu]ATSM is a positron emission tomography (PET) radiotracer for tumor hypoxia imaging.</abstract>

[61Cu]diacetyl-bis(N4-methylthiosemicarbazone) ([61Cu] ATSM) was prepared using in house-made diacetyl-bis(N4-methylthiosemicarbazone) (ATSM) ligand and [61Cu]CuCl2 produced via the natZn(p, x)61Cu (180 μA proton irradiation, 22 MeV, 3.2 h) and purified by a ion chromatography method. [61Cu]ATSM radiochemical purity was >98 %, as shown by HPLC and RTLC methods. [61Cu]ATSM was administered into normal and tumor bearing rodents for up to 210 minutes, followed by biodistribution and co-incidence imaging studies. Significant tumor/non-tumor accumulation was observed either by animal sacrification or imaging. [61Cu]ATSM is a positron emission tomography (PET) radiotracer for tumor hypoxia imaging.

Preclinical studies of [61Cu]ATSM as a PET radiopharmaceutical for fibrosarcoma imaging

Nuclear Medicine Research Group Agricultural, Medical and Industrial Research School (AMIRS), Karaj, Iran

Department of Medical Physics, School of Medicine University of Medical Sciences Hamadan, Iran

Acta Pharmaceutica

Preclinical studies of [Cu]ATSM as a PET radiopharmaceutical for fibrosarcoma imaging

[61Cu]diacetyl-bis(N4-methylthiosemicarbazone) ([61Cu] ATSM) was prepared using in house-made diacetyl-bis(N4-methylthiosemicarbazone) (ATSM) ligand and...

Preclinical studies of [⁶¹Cu]ATSM as a PET radiopharmaceutical for fibrosarcoma imaging

Online veröffentlicht: 20. März 2009

Seitenbereich: 45 - 55

DOI: https://doi.org/10.2478/v10007-009-0008-9

Schlüsselwörter
radiofarmak, bakar-61, [Cu]ATSM, hipoksija, pozitronska tomografija, fibrosarkom, snimanje

This content is open access.